Advanced Medical Solutions Group plc
("AMS", the "Company"
or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing
technologies, announces that it was notified on 28
March 2024 that on the same day Chris
Meredith, who is a Director and PDMR, had sold 40,500 Ordinary
Shares of 5p held on his behalf held in the name
of Platform Securities Nominees Limited ("Nominee"), at a price of
196.15p per Ordinary Share.
On the same day, the Company was
also informed that at the same time Individual
Savings Accounts ("ISA's") held in the name of Chris
Meredith purchased 5,160 Ordinary Shares of 5p, ISA's held
in the name of Ingrid Meredith purchased
3,792 Ordinary Shares of 5p, ISA's in the name of Chris Meredith's
PCA's purchased 26,472 Ordinary Shares of 5p and that Lifetime
Individual Savings Accounts ("LISA's") held in the
name of Chris Meredith's PCA's purchased 5,076 Ordinary
Shares of 5p, all at a price of 196.2p per Ordinary
Share.
The number of shares, and the
beneficial ownership of the shares, held by Chris Meredith, Ingrid
Meredith and his PCA's remains unchanged. These transactions are
part of normalised tax planning.
The notification below, made in
accordance with the requirements of the EU Market Abuse Regulation,
provides further detail.
1.
|
Details of the person discharging
managerial responsibilities/person closely
associated
|
|
a)
|
Name: Chris Meredith
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status:
Director
|
|
b)
|
Initial
notification/Amendment: Initial Notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name:
Advanced Medical Solutions Group plc
|
|
b)
|
LEI: 213800HJP6OWOSZI1L74
|
4.
|
Details of the transaction(s): section
to be repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the
financial instrument, type of instrument: Ordinary Shares of
5p
Identification code:
GB0004536594
|
|
b)
|
Nature of the
transactions:
·
Sale of 5,160 Ordinary Shares of 5p
held in the name of the Nominee
·
Purchase of 5,160 Ordinary Shares of 5p
into ISA's held in the name of Chris
Meredith
|
|
c)
|
Price(s) and
volume(s):
Sale of
shares:
|
Price(s)
|
Volume(s)
|
|
Sale of shares from
Nominee holding at 196.15p per share
|
5,160
|
|
Purchase by ISA's at
196.2p per share
|
5,160
|
|
|
d)
|
Aggregated
information: (Relates to those shares sold only)
Aggregated volume:
5,160
Aggregated price:
196.15p
|
|
e)
|
Date of the
transaction: 28/03/2024
|
|
f)
|
Place of the
transaction: London Stock Exchange, AIM Market (XLON)
|
1.
|
Details of the person discharging
managerial responsibilities/person closely
associated
|
|
a)
|
Name: Chris Meredith
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status:
Director
|
|
b)
|
Initial
notification/Amendment: Initial Notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name:
Advanced Medical Solutions Group plc
|
|
b)
|
LEI: 213800HJP6OWOSZI1L74
|
4.
|
Details of the transaction(s): section
to be repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the
financial instrument, type of instrument: Ordinary Shares of
5p
Identification code:
GB0004536594
|
|
b)
|
Nature of the
transactions:
·
Sale of 3,792 Ordinary Shares of 5p
held in the name of the Nominee
·
Purchase of 3,792 Ordinary Shares of 5p
into ISA's held in the name of Ingrid
Meredith
|
|
c)
|
Price(s) and
volume(s):
Sale of
shares:
|
Price(s)
|
Volume(s)
|
|
Sale of shares from
Nominee holding at 196.15p per share
|
3,792
|
|
Purchase by ISA's at
196.2p per share
|
3,792
|
|
|
d)
|
Aggregated
information: (Relates to those shares sold only)
Aggregated volume:
3,792
Aggregated price:
196.15p
|
|
e)
|
Date of the
transaction: 28/03/2024
|
|
f)
|
Place of the
transaction: London Stock Exchange, AIM Market (XLON)
|
1.
|
Details of the person discharging
managerial responsibilities/person closely
associated
|
|
a)
|
Name: Chris Meredith
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status:
Director
|
|
b)
|
Initial
notification/Amendment: Initial Notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name:
Advanced Medical Solutions Group plc
|
|
b)
|
LEI: 213800HJP6OWOSZI1L74
|
4.
|
Details of the transaction(s): section
to be repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the
financial instrument, type of instrument: Ordinary Shares of
5p
Identification code:
GB0004536594
|
|
b)
|
Nature of the
transactions:
·
Sale of 26,472 Ordinary Shares of 5p
held in the name of the Nominee
·
Purchase of 26,472 Ordinary Shares of 5p
into ISA's held in the name of Chris Meredith's
PCA's
|
|
c)
|
Price(s) and
volume(s):
Sale of
shares:
|
Price(s)
|
Volume(s)
|
|
Sale of shares from
Nominee holding at 196.15p per share
|
26,472
|
|
Purchase by ISA's at
196.2p per share
|
26,472
|
|
|
d)
|
Aggregated
information: (Relates to those shares sold only)
Aggregated volume:
26,472
Aggregated price:
196.15p
|
|
e)
|
Date of the
transaction: 28/03/2024
|
|
f)
|
Place of the
transaction: London Stock Exchange, AIM Market (XLON)
|
1.
|
Details of the person discharging
managerial responsibilities/person closely
associated
|
|
a)
|
Name: Chris Meredith
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status:
Director
|
|
b)
|
Initial
notification/Amendment: Initial Notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name:
Advanced Medical Solutions Group plc
|
|
b)
|
LEI: 213800HJP6OWOSZI1L74
|
4.
|
Details of the transaction(s): section
to be repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the
financial instrument, type of instrument: Ordinary Shares of
5p
Identification code:
GB0004536594
|
|
b)
|
Nature of the
transactions:
·
Sale of 5,076 Ordinary Shares of 5p
held in the name of the Nominee
·
Purchase of 5,076 Ordinary Shares of 5p
into LISA's held in the name of Chris Meredith's
PCA's
|
|
c)
|
Price(s) and
volume(s):
Sale of
shares:
|
Price(s)
|
Volume(s)
|
|
Sale of shares from
Nominee holding at 196.15p per share
|
5,076
|
|
Purchase by LISA's at
196.2p per share
|
5,076
|
|
|
d)
|
Aggregated
information: (Relates to those shares sold only)
Aggregated volume:
5,076
Aggregated price:
196.15p
|
|
e)
|
Date of the
transaction: 28/03/2024
|
|
f)
|
Place of the
transaction: London Stock Exchange, AIM Market (XLON)
|
- End -
For
further information, please visit www.admedsol.com
or
contact:
|
Advanced Medical Solutions Group plc
|
Tel: +44
(0) 1606 545508
|
|
Chris Meredith, Chief Executive
Officer
Eddie Johnson, Chief Financial
Officer
Michael King, Investor
Relations
|
|
|
|
|
|
ICR
Consilium
|
Tel: +44
(0) 20 3709 5700
|
|
Mary-Jane Elliott
/ Lucy
Featherstone
|
AMS@consilium-comms.com
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker)
|
Tel: +44
(0) 20 7597 5970
|
|
Gary Clarence / David
Anderson
|
|
|
|
|
|
HSBC Bank PLC (Broker)
|
Tel: 44
(0) 20 7991 8888
|
|
Sam McLennan / Joe Weaving /
Stephanie Cornish
|
|
About Advanced Medical Solutions Group plc
-
see www.admedsol.com
AMS is a world-leading independent
developer and manufacturer of innovative tissue-healing technology,
focused on quality outcomes for patients and value for payers. AMS
has a wide range of surgical products including tissue adhesives,
sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®,
RESORBA®, LiquiBandFix8® and
Seal-G®. AMS also supplies wound care dressings such as
silver alginates, alginates and foams through its
ActivHeal® brand as well as under white label.
Since 2019, the Group has made five acquisitions: Sealantis, an
Israeli developer of innovative internal sealants; Biomatlante, a
French developer and manufacturer of surgical biomaterials,
Raleigh, a leading UK coater and converter of woundcare and
bio-diagnostics materials, AFS Medical, an Austrian specialist
surgical business and Connexicon, an Irish tissue adhesives
specialist.
AMS's products, manufactured in the
UK, Germany, France, the Netherlands, the Czech Republic and
Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct
sales forces in the UK, Germany, the Czech Republic and Russia. The
Group has R&D innovation hubs in the UK, Ireland, Germany,
France and Israel. Established in 1991, the Group has more than 900
employees. For more information, please see
www.admedsol.com.